Evaluation of multiple recurrence events in superficial bladder cancer patients treated with intravesical bacillus Calmette-Guérin therapy using the Andersen-Gill's model

摘要: To evaluate factors affecting recurrenceafter intravesical bacillus Calmette-Guerin(BCG) therapy (Tokyo 172 strain), we revieweddata for 101 patients with superficial bladdercancer (pTa [n = 80] and pT1 21]) treatedbetween 1985 1999. The median follow-upperiod was 58.9 months. Factors thefirst tumour recurrence were evaluated usingCox's proportional hazards model thoseaffecting multiple withAndersen-Gill's model. 5-yearrecurrence-free rate 63% all 101patients. frequency, defined astimes per 100 patient-months of follow-up,greatly decreased from 7.3 ± 9.6 (SD) beforethe instillation to 2.6 5.6 after thetherapy (p < 0.0001). Patients pT1tumours tended have earlier thanthose pTa tumours 0.06). Multivariateanalysis using Cox's modelrevealed that a history bladder cancer andpathological stage independent factorsaffecting the first theBCG therapy. When endpoints ofrecurrence theAndersen-Gill's model, number aswell as demonstrated significantlinks BCGtherapy. 5-year progression-free 5-yearsurvival rates 89.3% 85.3% allthe patients, respectively. Becauseintravesical may involve multipleevents during clinical course patientswith cancer, Andersen-Gill's modelappears useful evaluation riskfactors.